BioMarin Gears Up To Give Roctavian Another Go
Voxzogo Sales Could Exceed $100m
The company is aiming for an outcomes-based payment model in the US, while it is confident the gene therapy will fare better than some others have in Europe.
The company is aiming for an outcomes-based payment model in the US, while it is confident the gene therapy will fare better than some others have in Europe.